Eli Lilly announced Huntsville, Alabama, as the site for a $6 billion active pharmaceutical ingredient (API) manufacturing facility that will produce peptide and small‑molecule APIs, including the GLP‑1 oral candidate orforglipron. The plant is the third of four major U.S. manufacturing sites Lilly is building to onshore API supply and expand capacity. Lilly projects the facility will create 450 permanent jobs and thousands of construction roles; the company cited proximity to training partners and a skilled workforce as decision factors. The investment is part of a broader strategy to strengthen supply‑chain resilience for high‑demand therapies, particularly obesity and metabolic drugs. For the sector, the announcement highlights accelerating onshoring of critical APIs by large pharma in response to supply‑chain risk, strategic product demand, and political pressure to localize manufacturing.